ea0028p56 | Clinical practice/governance and case reports | SFEBES2012
Gurazada Kalyan
, Marshall Neal
, Johnson Margaret
, Hillman Tobias
, Bouloux Pierre
, Khoo Bernard
The HIV protease inhibitor (PI) ritonavir is used in conjunction with other antiretroviral treatments as a pharmacokinetic booster due to its potent inhibition of hepatic cytochrome P450 3A4 (CYP3A4). Co-administration of glucocorticoids metabolized by CYP3A4, with ritonavir leads to accumulation of these glucocorticoids, markedly increasing the risk of iatrogenic Cushings syndrome and suppression of the Hypothalamic-Pituitary-Adrenal axis. We present 11 patients receivi...